1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2016

Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2016" provides an overview of Dry (Atrophic) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials 28
Prominent Drugs 30
Clinical Trial Profile Snapshots 31
Appendix 63
Abbreviations 63
Definitions 63
Research Methodology 64
Secondary Research 64
About GlobalData 65
Contact Us 65
Disclaimer 65
Source 66

List of Tables
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2016* 6
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 15
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 18
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 15
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 18
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 64

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
North America Vitreo Retinal Surgery Devices Market Outlook to 2022

North America Vitreo Retinal Surgery Devices Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

North America Vitreo Retinal Surgery Devices Market Outlook to 2022 Summary GlobalData’s new report, "North America Vitreo Retinal Surgery Devices Market Outlook to 2022", provides key market data on ...

EU5 Ophthalmic Lasers Market Outlook to 2022

EU5 Ophthalmic Lasers Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

EU5 Ophthalmic Lasers Market Outlook to 2022 Summary GlobalData’s new report, "EU5 Ophthalmic Lasers Market Outlook to 2022", provides key market data on the EU5 Ophthalmic Lasers market. The report ...

BRIC Ophthalmic Lasers Market Outlook to 2022

BRIC Ophthalmic Lasers Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

BRIC Ophthalmic Lasers Market Outlook to 2022 Summary GlobalData’s new report, "BRIC Ophthalmic Lasers Market Outlook to 2022", provides key market data on the BRIC Ophthalmic Lasers market. The report ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.